QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia.
A global trial will test whether a drug already helping certain leukemia patients might extend survival in a leukemia type with few treatment options.
This report describes the rationale and design of QuANTUM-Wild, a global Phase III trial testing whether quizartinib—already approved for FLT3-ITD-positive AML—can extend survival in FLT3-ITD-negative AML where <50% of patients survive 5 years and treatment options remain limited. The 3-arm design specifically isolates the maintenance phase contribution, which will provide mechanistic insight into FLT3 pathway inhibition independent of mutation status.
What the study was
- Study design
- phase_III_rct_protocol
- Population
- Newly diagnosed FLT3-ITD-negative AML
- Sample size
- ~700 (planned)
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Future Oncology
Why it surfaced
FLT3-neg AML represents ~70% of AML cases and has significant unmet need; quizartinib Phase III enrollment is a major pipeline signal; international investigator-sponsored multi-arm design is rigorous; Daiichi Sankyo sponsorship indicates commercial development trajectory.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.